一分钟看懂
这是一项关于Oral Squamous Cell Carcinoma (OSCC)的II 期研究，登记的药物或干预包括Rimegepant；Tislelizumab；Nab-paclitaxel；Cisplatin，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Rimegepant；Tislelizumab；Nab-paclitaxel；Cisplatin · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Zhongshan Hospital, Fudan University · 上海
公开的入选条件
- * Age 18 to 75 years, regardless of sex.
- * Histologically or cytologically confirmed oral or oropharyngeal squamous cell carcinoma, including primary disease or recurrent disease after previous treatment that is considered amenable to repeat curative-intent resection.
- * Planned to receive neoadjuvant chemoimmunotherapy followed by surgery after multidisciplinary evaluation.
- * At least one evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1.
- * Eastern Cooperative Oncology Group performance status of 0 or 1.
- * Adequate major organ function.
- * Voluntary participation and provision of written informed consent.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07812467；登记信息更新于 2026-09-10。